Immunotherapy for malignant glioma

Surgical Neurology International

Volumn 6, Issue 2, 2015, Pages S68-S77

  Suryadevara, Carter ^a,b   Verla, Terence ^a,b   Sanchez Perez, Luis ^a,b   Reap, Elizabeth ^a,b   Choi, Bryan ^c   Fecci, Peter ^a,b   Sampson, John ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adoptive cell transfer; Brain tumors; Central nervous system; Glioma; Immunotherapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR VARIANT III; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; RINDOPEPIMUT; SINGLE CHAIN VARIABLE FRAGMENT CD28 ANTIGEN CD137 ANTIGEN CD3 ZETA; TUMOR VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADOPTIVE CELL TRANSFER; ANTIGEN RECOGNITION; BLOOD BRAIN BARRIER; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; CENTRAL NERVOUS SYSTEM; GLIOBLASTOMA; HUMAN; IMMUNE PRIVILEGE; IMMUNITY; IMMUNOEDITING; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE RECEPTOR GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY;

EID: 84930387479     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.151341     Document Type: Review

References (125)

1. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: Findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 2013;41:33-9.
2. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008;10:619-24.
3. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: Different roles for microglia and astrocytes. Immunol Today 2000;21:141-7.
4. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al. CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
5. Atkins MB, Lotze M T, Dutcher J P, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
6. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H. Human CD4+CD25+regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516-20.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6:1251-9.
8. Boockvar JA, Kapitonov D, Kapoor G, Schouten J, Counelis GJ, Bogler O, et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 2003;24:1116-30.
9. Brentjens R, Ye h R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666-8.
10. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra138.
11. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
12. Bullard DE, Gillespie GY, Mahaley MS, Bigner DD. Immunobiology of human gliomas. Semin Oncol 1986;13:94-109.
13. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010;2010:956304.
14. Chen W. Dendritic cells and (CD4+) CD25+T regulatory cells: Crosstalk between two professionals in immunity versus tolerance. Front Biosci 2006;11:1360-70.
15. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009;19:713-23.
16. Choi BD, Gedeon PC, Herndon JE 2nd, Archer GE, Reap EA, Sanchez-Perez L, et al. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecifc antibody. Cancer Immunol Res 2013;1:163.
17. Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecifc antibody. Oncoimmunology 2013;2:e26757.
18. Choi BD, Kuan C T, Cai M, Archer GE, Mitchell DA, Gedeon PC, et al. Systemic administration of a bispecifc antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A 2013;110:270-5.
19. Choi BD, Pastan I, Bigner DD, Sampson JH. A novel bispecifc antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology 2013;2:e23639.
20. Choi BD, Suryadevara CM, Gedeon PC, Herndon Ii JE, Sanchez-Perez L, Bigner DD, et al. Intracerebral delivery of a third generation EGFRvIII-specifc chimeric antigen receptor is effcacious against human glioma. J Clin Neurosci 2014;21:189-90.
21. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997;324:855-61.
22. Croft M. Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-20.
23. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view. Immunol Today 1992;13:507-12.
24. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
25. Dandy WE. Removal of right cerebral hemisphere for certain tumors with hemiplegia-Preliminary report. JAMA 1928;90:823-5.
26. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V. Myeloid-derived suppressor cell role in tumor-related infammation. Cancer Lett 2008;267:216-25.
27. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;14 Suppl 5:v1-49.
28. Dudley ME, Wunderlich JR, Robbins P F, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
29. Dunn G P, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
30. Dunn G P, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery 2012;71:201-22.
31. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte traffcking to the CNS: Anatomical sites and molecular mechanisms. Trends Immunol 2005;26:485-95.
32. Eshhar Z, Waks T, Gross G, Schindler DG. Specifc activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-4.
33. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS. Immunol Today 1994;15:218-24.
34. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294-302.
35. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
36. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
37. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 2002;98:357-61.
38. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: Intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995;20:269-87.
39. Golovina TN, Vonderheide RH. Regulatory T cells: Overcoming suppression of T-cell immunity. Cancer J 2010;16:342-7.
40. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-9.
41. Hart DN, Fabre JW. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J Exp Med 1981;154:347-61.
42. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6.
43. Heimberger AB, Sampson JH. Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma? Neuro Oncol 2011;13:3-13.
44. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9:1087-98.
45. Hentschel SJ, Lang FF. Current surgical management of glioblastoma. Cancer J 2003;9:113-25.
46. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS infammation. Brain Pathol 1991;1:97-105.
47. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006;8:261-79.
48. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
49. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676-84.
50. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 1990;28:818-22.
51. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731-45.
52. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is suffcient to couple to receptor-associated signal transduction pathways. Cell 1991;64:891-901.
53. Jensen MC, Popplewell L, DiGiusto D, Kalos M, Raubitschek A, Forman SJ. A frst-in-human clinical trial of adoptive therapy using CD19-specifc chimeric antigen receptor re-directed T-cells for recurrent/refractory follicular lymphoma. Blood 2007;110:92a.
54. Jia W, Jackson-Cook C, Graf MR. Tumor-infltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma+vaccination model. J Neuroimmunol 2010;223:20-30.
55. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
56. Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep 2010;10:259-66.
57. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
58. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modifed T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15.
59. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694-705.
60. Klebanoff CA, Acquavella N, Yu Z, Restifo N P. Therapeutic cancer vaccines: Are we there yet? Immunol Rev 2011;239:27-44.
61. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 2006;24:e20-2.
62. Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 2004;72:267-73.
63. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: Direct suppression of B cells by CD4+CD25+regulatory T cells. J Immunol 2005;175:4180-3.
64. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
65. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-5.
66. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR. Brain microenvironment promotes the fnal functional maturation of tumor-specifc effector CD8+T cells. J Immunol 2007;179:845-53.
67. Matsukado Y, Maccarty CS, Kernohan JW. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 1961;18:636-44.
68. Matyszak MK, Denis-Donini S, Citterio S, Longhi R, Granucci F, Ricciardi-Castagnoli P. Microglia induce myelin basic protein-specifc T cell anergy or T cell activation, according to their state of activation. Eur J Immunol 1999;29:3063-76.
69. Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, et al. EGFRvIII-specifc chimeric antigen receptor T cells migrate to and kill tumor deposits infltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PloS One 2014;9:e94281.
70. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011;118:3003-12.
71. Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer J 2003;9:157-66.
72. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev 2008;222:70-100.
73. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
74. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modifed T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012;23:1043-53.
75. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
76. Moritz D, Groner B. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for effcient ligand binding and signaling activity. Gene Ther 1995;2:539-46.
77. Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P. CD25+CD4+T cells contribute to the control of memory CD8+T cells. Proc Natl Acad Sci U S A 2002;99:8832-7.
78. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56:5079-86.
79. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013;310:1842-50.
80. Parish CR. Cancer immunotherapy: The past, the present and the future. Immunol Cell Biol 2003;81:106-13.
81. Parsa AT, Waldron JS, Panner A, Crane CA, Parney I F, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-8.
82. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010;98:93-9.
83. Pelloski CE, Ballman K V, Furth A F, Zhang L, Lin E, Sulman E P, et al. Epidermal growth factor receptor variant III status defnes clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-94.
84. Platten M, Wick W, Weller M. Malignant glioma biology: Role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001;52:401-10.
85. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specifc T cells engineered to coexpress tumor-specifc receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70.
86. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12:933-41.
87. Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, et al. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 2004;173:6472-80.
88. Romeo C, Amiot M, Seed B. Sequence requirements for induction of cytolysis by the T cell antigen/Fc receptor zeta chain. Cell 1992;68:889-97.
89. Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps128.
90. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
91. Rosenberg SA, Restifo N P, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
92. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
93. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
94. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores C T, et al. EGFRvIII mCAR-modifed T cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2014;20:972-84.
95. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, et al. Unarmed, tumor-specifc monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000;97:7503-8.
96. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9.
97. Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PloS One 2012;7:e31046.
98. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modifed T cells in lymphoma patients. J Clin Invest 2011;121:1822-6.
99. Schneider S W, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, Senner V, et al. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 2004;107:272-6.
100. Sehgal A, Berger MS. Basic concepts of immunology and neuroimmunology. Neurosurg Focus 2000;9:e1.
101. Semenza GL. Defning the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
102. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, et al. 4-1BB costimulatory signals preferentially induce CD8+T cell proliferation and lead to the amplifcation in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
103. Sica G, Chen L. Modulation of the immune response through 4-1BB. Adv Exp Med Biol 2000;465:355-62.
104. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: A balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005;54:1137-42.
105. Soda Y, Myskiw C, Rommel A, Verma IM. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med 2013;91:439-48.
106. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-73.
107. Stevens A, Kloter I, Roggendorf W. Infammatory infltrates and natural killer cell presence in human brain tumors. Cancer 1988;61:738-43.
108. Stupp R, Dietrich P Y, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
109. Stupp R, Mason W P, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
110. Tada M, Suzuki K, Yamakawa Y, Sawamura Y, Sakuma S, Abe H, et al. Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8 (77)). J Neurooncol 1993;16:25-34.
111. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fde CD8 T cell survival signal. J Immunol 1999;162:5037-40.
112. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modifed autologous CD20-specifc T cells. Blood 2008;112:2261-71.
113. Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, Murillo O, et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 2006;66:2442-50.
114. Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A. CD4+CD25+T regulatory cells inhibit cytotoxic activity of T CD8+and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004;112:258-67.
115. Trzonkowski P, Szmit E, Mysliwska J, Mysliwski A. CD4+CD25+T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin Immunol 2006;119:307-16.
116. Wei S, Egenti MU, Teitz-Tennenbaum S, Zou W, Chang AE. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother 2013;36:124-32.
117. Wikstrand CJ, Bigner DD. Immunobiologic aspects of the brain and human gliomas. A review. Am J Pathol 1980;98:517-68.
118. Wikstrand CJ, Hale L P, Batra SK, Hill ML, Humphrey PA, Kurpad SN, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55:3140-8.
119. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
120. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
121. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specifc CD8+T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73.
122. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261-5.
123. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, et al. A herceptin-based chimeric antigen receptor with modifed signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009;183:5563-74.
124. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/ AKT/Bcl-XL activation and CD8+T cell-mediated tumor eradication. Mol Ther 2010;18:413-20.
125. Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, et al. Adoptive cell therapy with autologous tumor-infltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Exp Ther Med 2012;3:898-902.